{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:40:04Z","timestamp":1778931604889,"version":"3.51.4"},"reference-count":80,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background\/Objectives: Fabry Disease (FD) is a multisystem X-linked lysosomal storage disorder that often manifests with nonspecific gastrointestinal (GI) symptoms, such as abdominal pain, diarrhea, and constipation. These symptoms may appear early in childhood, severely impacting quality of life and delaying diagnosis, and may be linked to nutritional challenges. This systematic review aims to evaluate the prevalence, characteristics, clinical relevance, and nutritional aspects of GI manifestations in pediatric FD patients to aid in early recognition and improve outcomes. Methods: A systematic literature search with meta-analysis adhering to PRISMA and MOOSE guidelines was conducted across PubMed, Web of Science, and Google Scholar from inception to November 2024 using fixed inclusion and exclusion criteria. Data were extracted by two reviewers independently. Disagreements were resolved by consensus; a third reviewer was consulted, when necessary. Pooled analysis was performed by a random-effects model; heterogeneity was assessed using the I2 method. A quality assessment appraisal of the studies was carried out using the ROBINS-I tool. Results: The review encompassed 18 studies involving 736 pediatric patients. The evaluation of the pooled prevalence of GI symptoms in FD patients was 53% (95% CI 38\u201368%, I2 90%), with abdominal pain being the most frequent (pooled prevalence of 46% (95% CI 33\u201360%, I2 86%)). Symptoms often presented early, with a summarized standardized mean difference between the mean age of symptom onset and the mean age at FD diagnosis of 2.07 years (95% CI of 0.56\u20133.57, I2 42%, p &lt; 0.01). Nutritional issues, including reduced food intake and potential malabsorption, were reported in cases with severe GI symptoms, contributing to growth impairments. Conclusions: GI symptoms frequently constitute the earliest clinical manifestation of FD in children. Their nonspecific nature underscores the importance of heightened clinical suspicion for timely diagnosis. Early intervention, including enzyme replacement therapy and tailored nutritional strategies, can alleviate symptoms, improve quality of life, and prevent disease progression. Multidisciplinary approaches are essential to optimize patient outcomes and further research into the pathophysiology and management of GI symptoms in FD is warranted.<\/jats:p>","DOI":"10.3390\/nu17071194","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T01:59:36Z","timestamp":1743386376000},"page":"1194","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Unraveling the Hidden Burden of Gastrointestinal and Nutritional Challenges in Children with Fabry Disease: A Systematic Review with Meta-Analysis"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6564-4788","authenticated-orcid":false,"given":"Vanessa Nadia","family":"Dargenio","sequence":"first","affiliation":[{"name":"Interdisciplinary Department of Medicine, Pediatric Section, Children\u2019s Hospital Giovanni XXIII, University of Bari Aldo Moro, 70126 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Natale","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, Pediatric Section, Children\u2019s Hospital Giovanni XXIII, University of Bari Aldo Moro, 70126 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania Paola","family":"Castellaneta","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, Pediatric Section, Children\u2019s Hospital Giovanni XXIII, University of Bari Aldo Moro, 70126 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni la","family":"Grasta","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, Pediatric Section, Children\u2019s Hospital Giovanni XXIII, University of Bari Aldo Moro, 70126 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Paulucci","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, Pediatric Section, Children\u2019s Hospital Giovanni XXIII, University of Bari Aldo Moro, 70126 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costantino","family":"Dargenio","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, Pediatric Section, Children\u2019s Hospital Giovanni XXIII, University of Bari Aldo Moro, 70126 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4603-974X","authenticated-orcid":false,"given":"Ruggiero","family":"Francavilla","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, Pediatric Section, Children\u2019s Hospital Giovanni XXIII, University of Bari Aldo Moro, 70126 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5849-8110","authenticated-orcid":false,"given":"Fernanda","family":"Cristofori","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, Pediatric Section, Children\u2019s Hospital Giovanni XXIII, University of Bari Aldo Moro, 70126 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.2174\/13816128113199990347","article-title":"Gastroenterological Complications of Anderson-Fabry Disease","volume":"19","author":"Buda","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.2174\/13816128113199990352","article-title":"Anderson-Fabry Disease: A Multiorgan Disease","volume":"19","author":"Tuttolomondo","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000060184","article-title":"Fabry disease (\u03b1-Galactosidase a deficiency): Renal Involvement and enzyme replacement therapy","volume":"136","author":"Desnick","year":"2001","journal-title":"Contrib. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J. Med. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02186.x","article-title":"Clinical manifestations of Fabry disease in children: Data from the Fabry Outcome Survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr. Int. J. Paediatr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.dld.2018.02.011","article-title":"Non-specific gastrointestinal features: Could it be Fabry disease?","volume":"50","author":"Hilz","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/DDDT.S11985","article-title":"Update on role of agalsidase alfa in management of Fabry disease","volume":"5","author":"Ramaswami","year":"2011","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ymgme.2012.08.003","article-title":"Enzyme replacement therapy in patients with Fabry disease: State of the art and review of the literature","volume":"107","author":"Pisani","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","article-title":"Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy\u2014A retrospective analysis from the Fabry outcome survey","volume":"23","author":"Hoffmann","year":"2007","journal-title":"Clin. J. Pain"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","article-title":"MOOSE Reporting Guidelines for Meta-analyses of Observational Studies","volume":"156","author":"Brooke","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_16","unstructured":"(2025, March 15). Risk of bias Tools. Available online: https:\/\/www.riskofbias.info\/welcome."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br. Med. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e64016","DOI":"10.2196\/64016","article-title":"MetaAnalysisOnline.com: Web-Based Tool for the Rapid Meta-Analysis of Clinical and Epidemiological Studies","volume":"27","author":"Fekete","year":"2025","journal-title":"J. Med. Internet Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: A study on 35 European children and adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur. J. Pediatr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","article-title":"Gastrointestinal Symptoms in 342 Patients With Fabry Disease: Prevalence and Response to Enzyme Replacement Therapy","volume":"5","author":"Hoffmann","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1651-2227.2007.00029.x","article-title":"Enzyme replacement therapy with agalsidase alfa in children with Fabry disease","volume":"96","author":"Ramaswami","year":"2007","journal-title":"Acta Paediatr. Int. J. Paediatr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and Efficacy of Enzyme Replacement Therapy with Agalsidase Beta: An International, Open-label Study in Pediatric Patients with Fabry Disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J. Pediatr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal Biopsy Findings in Children and Adolescents With Fabry Disease and Minimal Albuminuria","volume":"51","author":"Bostad","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","article-title":"Fabry disease in children: Agalsidase-beta enzyme replacement therapy","volume":"83","author":"Borgwardt","year":"2013","journal-title":"Clin. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wijburg, F.A., B\u00e9nichou, B., Bichet, D.G., Clarke, L.A., Dostalova, G., Fainboim, A., Fellgiebel, A., Forcelini, C., Haack, K.A., and Hopkin, R.J. (2015). Characterization of early disease status in treatment-naive male paediatric patients with fabry disease enrolled in a randomized clinical trial. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124987"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9712831","DOI":"10.1155\/2016\/9712831","article-title":"Gastrointestinal symptoms of patients with Fabry disease","volume":"2016","author":"Pensabene","year":"2016","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/cge.13007","article-title":"The mutation p.D313Y is associated with organ manifestation in Fabry disease","volume":"92","author":"Koehn","year":"2017","journal-title":"Clin. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13023-022-02417-3","article-title":"Burden associated with Fabry disease and its treatment in 12\u201315 year olds: Results from a European survey","volume":"17","author":"Bashorum","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gou, P., Leng, J., Cheng, X., and Zhang, J. (2023). Clinical evaluation, accurate diagnosis and treatment of four pedigrees with Fabry\u2019s disease. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1057014"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Li, Q., Wang, J., Tian, M., Yang, Z., Yu, L., Liu, S., Wang, C., Wang, X., and Sun, S. (2023). Clinical features and enzyme replacement therapy in 10 children with Fabry disease. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1084336"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13023-023-02806-2","article-title":"Low skeletal muscle mass as an early sign in children with fabry disease","volume":"18","author":"Lu","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Concolino, D., Rapsomaniki, M., Disabella, E., Sestito, S., Pascale, M.G., Moricca, M.T., Bonapace, G., Arbustini, E., and Strisciuglio, P. (2010). Co-existence of Phenylketonuria and Fabry disease on a 3 year-old boy: Case report. BMC Pediatr., 10.","DOI":"10.1186\/1471-2431-10-32"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.gtc.2005.02.008","article-title":"Irritable bowel syndrome: Epidemiology, natural history, health care seeking and emerging risk factors","volume":"34","author":"Cremonini","year":"2005","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00006231-199809000-00009","article-title":"Gastrointestinal symptoms and delayed gastric emptying in Fabry\u2019s disease","volume":"19","author":"Argoff","year":"1998","journal-title":"Nucl. Med. Commun."},{"key":"ref_38","first-page":"201","article-title":"Achalasia in an adolescent with Fabry disease","volume":"32","author":"Field","year":"2001","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00467-004-1462-8","article-title":"The co-existence of fabry and celiac diseases: A case report","volume":"19","author":"Dursun","year":"2004","journal-title":"Pediatr. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ymgme.2005.04.009","article-title":"Gastrointestinal manifestations of Fabry disease: Clinical response to enzyme replacement therapy","volume":"85","author":"Banikazemi","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"ref_41","first-page":"25","article-title":"Gastrointestinal phenotype of fabry disease in a patient with pseudoobstruction syndrome","volume":"4","author":"Buda","year":"2012","journal-title":"JIMD Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/jpc.12732","article-title":"Diagnostic dilemma and delay in Fabry disease: Insights from a case series of young female patients","volume":"51","author":"Ellaway","year":"2015","journal-title":"J. Paediatr. Child Health"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cge.12673","article-title":"Gastrointestinal involvement in Fabry disease. So important, yet often neglected","volume":"89","author":"Politei","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinbiochem.2014.09.018","article-title":"A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase A gene","volume":"48","author":"Tuttolomondo","year":"2015","journal-title":"Clin. Biochem."},{"key":"ref_45","first-page":"807","article-title":"Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients","volume":"32","author":"Skrunes","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_46","first-page":"100618","article-title":"Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres","volume":"24","author":"Mhanni","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1515\/jpem-2020-0056","article-title":"Analysis of the alpha galactosidase gene: Mutation profile and description of two novel mutations with extensive literature review in Turkish population","volume":"33","author":"Onay","year":"2020","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12969-021-00563-9","article-title":"Frequency of Fabry disease in a juvenile idiopathic arthritis cohort","volume":"19","author":"Cavalcante","year":"2021","journal-title":"Pediatr. Rheumatol."},{"key":"ref_49","first-page":"7","article-title":"Fetal pathology in Fabry\u2019s disease and mucopolysaccharidosis type I","volume":"34","author":"Elleder","year":"1998","journal-title":"Cesk. Patol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/1756283X16642936","article-title":"Understanding the gastrointestinal manifestations of Fabry disease: Promoting prompt diagnosis","volume":"9","author":"Karaa","year":"2016","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_51","first-page":"8","article-title":"Chronic intestinal pseudo-obstruction. Did you search for lysosomal storage diseases?","volume":"11","author":"Politei","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0016-5085(82)80262-X","article-title":"Pathophysiologic and Ultrastructural Basis for Intestinal Symptoms in Fabry\u2019s Disease","volume":"82","author":"Shnitka","year":"1982","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/gim.2014.120","article-title":"Fabry disease in infancy and early childhood: A systematic literature review","volume":"17","author":"Laney","year":"2015","journal-title":"Genet. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"85895","DOI":"10.18632\/oncotarget.13135","article-title":"Genetic variants associated with gastrointestinal symptoms in Fabry disease","volume":"7","author":"Scionti","year":"2016","journal-title":"Oncotarget"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Korterink, J.J., Diederen, K., Benninga, M.A., and Tabbers, M.M. (2015). Epidemiology of pediatric functional abdominal pain disorders: A meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126982"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2027852","DOI":"10.1080\/19490976.2022.2027852","article-title":"Fabry disease\u2013a multisystemic disease with gastrointestinal manifestations","volume":"14","author":"Lenders","year":"2022","journal-title":"Gut Microbes"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1097\/HJH.0b013e328336a077","article-title":"Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients","volume":"28","author":"Hilz","year":"2010","journal-title":"J. Hypertens."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Biegstraaten, M., van Schaik, I.N., Wieling, W., Wijburg, F.A., and Hollak, C.E.M. (2010). Autonomic neuropathy in Fabry disease: A prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests. BMC Neurol., 10.","DOI":"10.1186\/1471-2377-10-38"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1007\/s11136-021-02847-9","article-title":"FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrument","volume":"30","author":"Shields","year":"2021","journal-title":"Qual. Life Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","article-title":"The management and treatment of children with Fabry disease: A United States-based perspective","volume":"117","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: Cardiac outcomes after 10 years\u2019 treatment","volume":"10","author":"Kampmann","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_64","first-page":"45","article-title":"Improvement of fabry disease-related gastrointestinal symptoms in a significant proportion of female patients treated with agalsidase beta: Data from the fabry registry","volume":"38","author":"Wilcox","year":"2018","journal-title":"JIMD Rep."},{"key":"ref_65","first-page":"148","article-title":"Accelerated transit of intestinal gas with simethicone","volume":"44","author":"Danhof","year":"1974","journal-title":"Obstet. Gynecol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000200726","article-title":"Effect of simethicone on lactulose-induced H2 production and gastrointestinal symptoms","volume":"49","author":"Friis","year":"1991","journal-title":"Digestion"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.numecd.2020.11.028","article-title":"Nutrition in adult patients with selected lysosomal storage diseases","volume":"31","author":"Carubbi","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Gugelmo, G., Vitturi, N., Francini-Pesenti, F., Fasan, I., Lenzini, L., Valentini, R., Carraro, G., Avogaro, A., and Spinella, P. (2023). Gastrointestinal Manifestations and Low-FODMAP Protocol in a Cohort of Fabry Disease Adult Patients. Nutrients, 15.","DOI":"10.3390\/nu15030658"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with fabry disease: Natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","article-title":"Nephrotic syndrome in adults","volume":"336","author":"Hull","year":"2008","journal-title":"BMJ"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"110664","DOI":"10.1016\/j.nut.2019.110664","article-title":"Could nutritional therapy take us further in our approaches to Fabry disease?","volume":"72","author":"Ravarotto","year":"2020","journal-title":"Nutrition"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/MNH.0000000000000073","article-title":"Dietary sodium restriction: A neglected therapeutic opportunity in chronic kidney disease","volume":"23","author":"Humalda","year":"2014","journal-title":"Current Opin. Nephrol. Hypertens."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40620-017-0435-5","article-title":"Diet and enteral nutrition in patients with chronic kidney disease not on dialysis: A review focusing on fat, fiber and protein intake","volume":"30","author":"Sabatino","year":"2017","journal-title":"J. Nephrol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.3748\/wjg.v23.i21.3771","article-title":"Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!","volume":"23","author":"Loghin","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1017\/S002966511000162X","article-title":"Flavonoids as anti-inflammatory agents","volume":"69","author":"Serafini","year":"2010","journal-title":"Proc. Nutr. Soc."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Sureda, A., del Mar Bibiloni, M., Julibert, A., Bouzas, C., Argelich, E., Llompart, I., Pons, A., and Tur, J.A. (2018). Adherence to the mediterranean diet and inflammatory markers. Nutrients, 10.","DOI":"10.3390\/nu10010062"},{"key":"ref_77","unstructured":"Mehta, A., Beck, M., and Sunder-Plassmann, G. (2025, January 20). Gastrointestinal manifestations of Fabry disease, Fabry Disease: Perspectives from 5 Years of FOS, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK11570\/."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1017\/S0007114515002093","article-title":"Low-grade inflammation, diet composition and health: Current research evidence and its translation","volume":"114","author":"Minihane","year":"2015","journal-title":"Br. J. Nutr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s00431-022-04459-y","article-title":"A therapeutic guide on pediatric irritable bowel syndrome and functional abdominal pain-not otherwise specified","volume":"181","author":"Rexwinkel","year":"2022","journal-title":"Eur. J. Pediatr."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ymgme.2018.12.187","article-title":"Liver-targeted AAV gene therapy vectors produced by a clinical scale manufacturing process result in high, continuous therapeutic levels of enzyme activity and effective substrate reduction in mouse model of Fabry disease","volume":"126","author":"Huston","year":"2019","journal-title":"Mol. Genet. Metab."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/7\/1194\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:05:10Z","timestamp":1760029510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/7\/1194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":80,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["nu17071194"],"URL":"https:\/\/doi.org\/10.3390\/nu17071194","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]}}}